Insights

Home Insights

As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project

As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project Gaithersburg, MD (30 December 2022) – BLA Regulatory, LLC, a full-service biopharma regulatory consultancy, congratulates ImmuneOnco Biomedical Technology (Shanghai) Co., Ltd. (ImmuneOnco) on receiving US FDA IND may proceed letter for IMM2520 project.  About IMM2520  IMM2520[1] is a CD47×PD-L1 […]